Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EDNRB | P24530 | 2/20 | 0.30 |
| ▸ | EDNRA | P25101 | 2/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179338 | 0.82 | LMNA (0.38) | MAPTMEN1KMT2A | |
| SCHEMBL1180465 | 0.81 | ESR1 (0.37) | POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1178998 | 0.78 | LMNA (0.35) | MAPTPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL1179282 | 0.76 | ALOX15 (0.47) | POLBKMT2ASMN1; SMN2EDNRBEDNRA | |
| SCHEMBL12871107 | 0.75 | POLB (0.39) | MAPTPOLBMEN1CYP1A2CYP2D6 | |
| SCHEMBL1178746 | 0.73 | LMNA (0.39) | POLBMEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1179462 | 0.72 | MAPT (0.32) | MAPTPOLBEDNRBEDNRANR1I2 | |
| SCHEMBL1179192 | 0.71 | KMT2A (0.40) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1179727 | 0.71 | HRH4 (0.33) | SMN1; SMN2 | |
| SCHEMBL11798851 | 0.71 | MAPT (0.41) | MAPTPOLBMEN1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | MAPT 3786/4885POLB 1308/4885MEN1 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.